Tom manages the direct co-investment programme at British Patient Capital. Prior to joining British Patient Capital, he was an investor at Foresight Group and EcoMachines Ventures before that. Earlier in his career he co-founded a biotech manufacturing startup called Puridify that sold to GE Healthcare and worked in investment banking at Deutsche Bank. He holds an MBA from London Business School and is a CFA Charterholder.
Steven Van Wyk
Eric HirschhornBank of New York Mellon
Paola Bergamaschi Broyd
Edwin van BommelABN AMRO Ventures
Lord Jonathan Evans
You may also be interested in…
Distinguished Board Director and Former Fortune 100 CIO, Annabelle Bexiga Joins Quantexa Board of Directors
Annabelle Bexiga is joining Quantexa’s board of directors after serving as the non-executive director for DWS Group.
Quantexa Chosen By UK Government for Big Data and Analytics Framework as Part of Supplier Ecosystem
Quantexa Certified as a Most Loved Workplace
Quantexa has become certified as a Most Loved Workplace®, backed by Best Practice Institute (BPI) research and analysis.
The Ethics and Use of Artificial Intelligence & Machine Learning in Fighting Insurance Fraud
Discover how insurers can leverage innovative technology to enable better, more ethical, and more intelligent decisions.
How to Combat Internal Fraud in a Hybrid Work Environment
The sudden shift to remote working has created even more opportunities for corrupt insiders to operate. Many experts believe the incidence of internal fraud is growing. But better analytics tools can help curb the rising risks – and here’s how.
Quantexa Named a Strong Performer In 2022 Analyst Report for AML Solutions
Quantexa has been named a ‘Strong Performer’ in The Forrester Wave™: Anti-Money-Laundering Solutions, Q3 2022.